Padcev Ejfv savings card: as little as $5 a dose with commercial insurance

Padcev Ejfv is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How to pay the least

Given by your care team

Billed by the clinic

Padcev Ejfv is given by a doctor or nurse, not picked up at a pharmacy.

Ask your care team or your plan what you’d pay before your visit.

Compare every option

Brand namePadcev Ejfv

Authorized genericenfortumab vedotin

Regular genericenfortumab vedotin

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldAsk the pharmacy

Same as Padcev Ejfv?

The original

–

Brand nameThe maker’s card

PADCEV Copay Assistance Program (PADCEV Support Solutions)

Savings card from Astellas and Pfizer

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $5 a dose

The card takes up to $25,000 a year off your co-pay.

In the maker’s words

“Eligible patients pay as little as $5 per dose and are enrolled in the program for 12 months.”

From the maker’s offer on padcev.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Padcev Ejfv itself, from the same company, sold without the brand name, and usually for less. For now Padcev Ejfv is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Padcev Ejfv is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

PADCEV is a Nectin-4-directed antibody and microtubule inhibitor conjugate indicated:

in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, for the treatment of adult patients with muscle invasive bladder cancer (MIBC).
in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC).
as a single agent for the treatment of adult patients with la/mUC who:
- ○have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and platinum-containing chemotherapy, or
- ○are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy.

Source: the FDA label for Padcev Ejfv (SEAGEN INC.), August 4, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to the clinic’s billing office.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/padcev-ejfv/